HAIFA, Israel, Nov. 16, 2010 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (DAX:PJT) today reported that the company will present two key aspects of its clinical trials -- quality and regulatory, at the Commercial Translation of Regenerative Medicine Conference in London, UK. Mrs. Chaya Mazouz, Pluristem's VP Clinical and Regulatory Affairs, will participate in a panel discussion, titled "Validatory pathways to optimize cell product quality." In addition, Mrs. Mazouz will present a case study which outlines the organization transformation needed from Phase I to commercialization. The conference will take place on November 18-19, 2010.
